Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia.

Levels of FGF23 and Sclerostin in COVID-19 patients will be detected and correlated to calcium levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia

NCT01660308

Hypophosphatemia

UNKNOWN

Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years

NCT06683222

Bone Density

RECRUITING NA

Study on the Correlation of Free Vitamin d With BMD and Fracture

NCT03605173

Osteoporosis

UNKNOWN NA

Diagnosis of Osteogenesis Imperfecta in Children

NCT03169192

Bone Disease, Metabolic

UNKNOWN

Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study

NCT02315248

Osteoporosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COVID 19 is a current worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 "SARS-CoV-2". Hypovitaminosis D and hypocalcaemia have been reported to be associated with COVID 19 infection, they are considered good biomarkers of clinical severity of COVID 19. Poor prognosis related to hypocalcemia is increased in elderly patients.

Fibroblast growth factor 23 and sclerostin are secreted from the bone, they decrease active vitamin D levels. Their levels and their relation to calcium levels in COVID-19 patients will be detected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mild to moderate COVID 19 patients

According to COVID 19 treatment guidelines of National Institutes of Health (NIH):

Mild illness that show symptoms like fever, cough, nausea, vomiting, sore throat, loss of taste \& smell but don't show dyspnea or abnormal chest imaging.

Moderate illness that show clinical or radiological lower respiratory disease with SpO2 \> 94% on room air.